You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

CLINICAL TRIALS PROFILE FOR EXEMESTANE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Exemestane

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002777 ↗	Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1996-05-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen. PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast cancer.
NCT00003418 ↗	Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer	Unknown status	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1998-02-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗	Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer	Unknown status	UNICANCER	Phase 3	1998-02-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗	Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer	Unknown status	International Collaborative Cancer Group	Phase 3	1998-02-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00010010 ↗	Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-06-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00010010 ↗	Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer	Completed	New York University School of Medicine	Phase 2	2000-06-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Exemestane

Condition Name

Chart
Table

Condition Name for Exemestane
Intervention	Trials
Breast Cancer	107
Breast Neoplasms	31
Metastatic Breast Cancer	29
HER2/Neu Negative	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Exemestane
Intervention	Trials
Breast Neoplasms	224
Neoplasms	10
Recurrence	6
Carcinoma	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Exemestane

Trials by Country

Map
Table

Trials by Country for Exemestane
Location	Trials
United States	986
Italy	122
China	108
Canada	101
Spain	100
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Exemestane
Location	Trials
Florida	43
Texas	43
California	43
New York	38
Tennessee	34
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Exemestane

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Exemestane
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	61
Phase 2/Phase 3	2
[disabled in preview]	149
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Exemestane
Clinical Trial Phase	Trials
Completed	97
Active, not recruiting	38
Recruiting	32
[disabled in preview]	67
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exemestane

Sponsor Name

Chart
Table

Sponsor Name for Exemestane
Sponsor	Trials
Pfizer	40
National Cancer Institute (NCI)	33
Novartis Pharmaceuticals	19
[disabled in preview]	20
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Exemestane
Sponsor	Trials
Other	240
Industry	157
NIH	36
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.